User profiles for HESHAM MOHAMED

Hesham A. Mohamed, Ph.D IEEE Senior Member

Associate Professor, Electronics Research Institute
Verified email at eri.sci.eg
Cited by 662

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

…, MB Bradley-Garelik, H Mohamed… - Blood, The Journal …, 2014 - ashpublications.org
This analysis explores the impact of early cytogenetic and molecular responses on the
outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase 3 …

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

…, A Hochhaus, P Rousselot, H Mohamed… - Blood, The Journal …, 2014 - ashpublications.org
We present long-term follow-up of a dasatinib phase 3 study of patients with imatinib-resistant/-intolerant
chronic myeloid leukemia (CML). In the CA180-034 study, 670 patients with …

Dasatinib in imatinib‐resistant or‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034

…, JE Cortes, J Milone, H Mohamed… - American journal of …, 2016 - Wiley Online Library
Dasatinib was approved at 100 mg once daily for imatinib‐resistant or ‐intolerant patients with
chronic myeloid leukemia (CML) in chronic phase, based on results of the phase 3 CA180…

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

…, J Brevard, P Henrick, H Mohamed… - The Lancet …, 2023 - thelancet.com
Background Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of
mutant isocitrate dehydrogenase 1 (IDH1). The aims for phase 1 of this phase 1/2 study were …

Printed millimeter-wave MIMO-based slot antenna arrays for 5G networks

AAR Saad, HA Mohamed - AEU-International Journal of Electronics and …, 2019 - Elsevier
In this work, a broadband millimeter-wave (mm-wave) multiple-input–multiple-output (MIMO)
antenna system for upcoming fifth generation (5G) networks is presented. The MIMO …

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

…, A Sedkov, J Brevard, PF Kelly, H Mohamed… - Neuro …, 2023 - academic.oup.com
Background Olutasidenib (FT-2102) is a highly potent, orally bioavailable, brain-penetrant
and selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aim of the study was …

[HTML][HTML] Flexible and frequency reconfigurable CPW-fed monopole antenna with frequency selective surface for IoT applications

AA Ibrahim, HA Mohamed, MA Abdelghany… - scientific reports, 2023 - nature.com
This paper proposes a flexible, frequency-reconfigurable monopole antenna design with
frequency selective surface (FSS) for Internet of Things (IoT) applications. The proposed …

Single‐fed 4G/5G multiband 2.4/5.5/28 GHz antenna

ME Yassin, HA Mohamed, EAF Abdallah… - IET Microwaves …, 2019 - Wiley Online Library
In this study, a single‐fed printed multiband antenna for 4G/5G wireless communication
systems is presented. The proposed multiband antenna consists of Franklin strip monopole …

Design and implementation of UWB slot-loaded printed antenna for microwave and millimeter wave applications

…, W Swelam, A Allam, MFA Sree, HA Mohamed - IEEE …, 2021 - ieeexplore.ieee.org
In this paper, single-layer ultra-Wide Band (UWB) microstrip patch antennas loaded with
asymmetrical U-shaped slot in both microwave and millimeter wave applications are presented. …

Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results from a prespecified analysis of the pivotal phase II study ELM …

…, J Li, M Ufkin, M Zhu, A Chaudhry, H Mohamed… - Blood, 2022 - ashpublications.org
Background Odronextamab is a hinge-stabilized, human IgG4-based CD20× CD3 bispecific
antibody (Ab) that binds CD20 on B cells and CD3 on T cells, triggering T-cell-mediated …